Parkinson's Disease Clinical Trials in Los Angeles

Showing 81-100 of 109 trials

Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial

NCT01076452

The goal of the second phase of the study is to determine if simultaneous bilateral subthalamic nucleus stimulation or simultaneous bilateral globus pallidus stimulation is more effective in reducing symptoms of Parkinson's Disease.

Parkinson's Disease

US Department of Veterans Affairs299 participantsStarted Apr 2002

Los Angeles, California, United States • San Francisco, California, United States • San Francisco, California, United States +11 more locations

COMPLETEDPhase 2< 1 mile

Safety of Urate Elevation in Parkinson's Disease

NCT00833690

The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease. This will determine whether it is appropriate to proceed with a larger study of inosine's ability to modify the rate of disability progression in PD.

Parkinson Disease

The Parkinson Study Group75 participantsStarted Jun 2009

Los Angeles, California, United States • Manchester, Connecticut, United States • New Haven, Connecticut, United States +13 more locations

Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial

Safety of Urate Elevation in Parkinson's Disease

Parkinson's Disease Trials in Other Cities

Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial

Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Memory Disorders Registry

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

PRISM Registry: Pseudobulbar Affect Registry Series

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

A Study of E2007 In Patients With Parkinson's Disease

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

Study of Antidepressants in Parkinson's Disease

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

Other Conditions in Los Angeles